Elsevier Announces NUTRACEUTICALS

CAMBRIDGE, MA - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Nutraceuticals: Efficacy, Safety and Toxicity, a first-of-its-kind reference detailing the use and potential toxic effects of nutraceuticals and dietary supplements. Elsevier also introduced the second edition of Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, its comprehensive and valuable working handbook on all aspects of drug research, discovery, design, development and optimization for scientists and students.

The two highly anticipated books, along with six additional new toxicology, pharmacology and pharmaceutical science titles, will be featured in Elsevier's ToxExpo booth # 901 at the Society of Toxicology (SOT) Annual Meeting, March 13-17 in New Orleans.

Edited by renowned Elsevier collaborator Dr. Ramesh Gupta, Nutraceuticals brings together all current knowledge regarding the potential toxic effects of nutraceuticals, herbal medicines, ayurvedic medicines, prebiotics, probiotics and adaptogens. This essential reference also looks at the judicious use of nutraceuticals, the best tools for their evaluation, and regulatory aspects from around the world.

• Download a sample chapter of Nutraceuticals here

Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, Second Edition is written by Li Di, an associate research fellow at Pfizer, and Edward Kerns, writer and consultant in Discovery ADME ?. This valuable resource explores physiochemical properties, including solubility and permeability, as well as how compounds are absorbed, distributed and metabolized safely and stably. The second edition includes expanded coverage of pharmacokinetics fundamentals and effects.

• Download a sample chapter of Drug-Like Properties here

The eight new toxicology, pharmacology and pharmaceutical science books are:

• Nutraceuticals: Efficacy, Safety and Toxicity by Ramesh Gupta
• Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, Second Edition by Li Di and Edward Kerns
• Advances in Molecular Toxicology, Volume 9 by James Fishbein and Jacqueline Heilman
• Engineered Nanoparticles: Structure, Properties and Mechanisms of Toxicity by Ashok Singh
• Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines, Second Edition by Tom Brody
• Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Sixteenth Edition by J. K. Aronson
• Social Aspects of Drug Discovery, Development and Commercialization by Odilia Osakwe and Syed Rizvi
• Pharmacy Practice in Developing Countries: Achievements and Challenges by Ahmed Fathelrahman, Mohamed Ibrahim and Albert Wertheimer

Four of Elsevier's editors will be participating in the SOT Annual Meeting program, and their books will be on display in booth # 901:

Jos Kleinjans, editor of Toxicogenomics-Based Cellular Models, will co-chair a morning course on "Next Generation Sequencing in Toxicogenomics" (Mar. 13, 8:15 am).

Gerhard Weinbauer, co-editor of The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment will co-chair the workshop session, "An Update on Juvenile Animal Testing" (Mar. 16, 9:30 am).

Michael Aschner, co-editor of Environmental Factors in Neurodevelopmental and Neurodegenerative Disorders, will speak during the mini-symposium on "Advances in Metal Toxicity" (Mar 16, 5:00 pm) and during the symposium session "Mitrochondrial Dysfunction as a Pathogenic Mechanism and Therapeutic Target for Neurogenerative Diseases" (Mar. 17, 9:30 am).

Gary Burleson, a section editor of Comparative Biology of the Normal Lung, Second Edition, is co-chairing the workshop session "Developmental Immunotoxicology-Are We Adequately Evaluating Safety?" (Mar. 17, 9:30 am).

Elsevier uses proprietary tools to identify knowledge gaps in fields such as toxicology, pharmacology and pharmaceutical science. Editorial teams then strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books are key examples of how Elsevier is enabling science to drive innovation.

The books are available on both the Elsevier Store and ScienceDirect, Elsevier's full-text scientific database offering journal articles and book chapters from over 2,500 peer-reviewed journals and more than 33,000 book titles.

Notes for Editors
E-book review copies of the books are available to credentialed journalists upon request. Contact Robin Hayward at R.Hayward@elsevier.com.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Image Available: http://www.marketwire.com/library/MwGo/2016/3/11/11G087187/Images/Drug-Like_Properties_cover-66d4d2e6f04b9236833f24cd484745f6.jpg
Image Available: http://www.marketwire.com/library/MwGo/2016/3/11/11G087187/Images/Nutraceuticals_cover-193fdd3a65739c5c886f5d90326c6cfb.jpg